Evotec SE logo

Evotec SENASDAQ: EVO

Profile

Sector:

Healthcare

Country:

Germany

IPO:

05 February 2004

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.36 B
-84%vs. 3y high
77%vs. sector
-vs. 3y high
-vs. sector
-83%vs. 3y high
46%vs. sector
-87%vs. 3y high
32%vs. sector

Price

pre-market | 91 min ago
$3.82+$0.01(+0.33%)

Dividend

No data over the past 3 years
$196.10 M$209.05 M
$196.10 M-$102.22 M

Analysts recommendations

Institutional Ownership

EVO Latest News

Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
accesswire.com30 October 2024 Sentiment: POSITIVE

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process.

Evotec and Bristol Myers Squibb Expand Proteomics Partnership
accesswire.com23 October 2024 Sentiment: POSITIVE

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a programme-based payment of US$ 50 m to Evotec.

Kia Gwangmyeong EVO Plant Opens to Significantly Expand EV Production
prnewswire.com26 September 2024 Sentiment: POSITIVE

Kia celebrates the completion of Hyundai Motor Group's first dedicated EV manufacturing facility Kia Gwangmyeong EVO Plant, located at Kia Autoland Gwangmyeong, to mass-produce Kia EV3 and EV4 models The new facility to have production capacity of 150,000 units per year Previous internal combustion engine (ICE) vehicle plant transformed to facilitate EV production and accelerate delivery of Kia's strategic sustainable manufacturing and mobility goals Cutting-edge manufacturing initiatives include water-based painting as well as automated processes The EVO Plant to set a new era for Kia's move towards electrification, through production of the brand's high quality EV lineup SEOUL, South Korea, Sept. 26, 2024 /PRNewswire/ -- Kia Corporation has today celebrated the opening of Kia Gwangmyeong EVO Plant, Hyundai Motor Group's (the Group) first dedicated EV manufacturing facility.

Evotec and Novo Nordisk forge technology development partnership
reuters.com26 September 2024 Sentiment: POSITIVE

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the company said on Thursday.

Evotec Announces Change in Management Board
accesswire.com03 September 2024 Sentiment: POSITIVE

Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions HAMBURG, GERMANY / ACCESSWIRE / September 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024.

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
zacks.com14 August 2024 Sentiment: POSITIVE

A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths
accesswire.com14 August 2024 Sentiment: NEUTRAL

Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024 Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been accelerated Challenging market environment and high fixed cost base led to weaker profitability.

Evotec SE (EVO) Q2 2024 Earnings Call Transcript
seekingalpha.com14 August 2024 Sentiment: POSITIVE

Evotec SE (NASDAQ:EVO ) Q2 2024 Earnings Conference Call August 14, 2024 8:00 AM ET Company Participants Volker Braun - Executive Vice President, Head of Global Investor Relations and ESG Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Matthias Evers - Chief Business Officer Craig Johnstone - Chief Operating Officer & Site Head Toulouse Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets Benjamin Jackson - Jefferies Michael Ryskin - Bank of America Steven Mah - TD Cowen Falko Friedrichs - Deutsche Bank Stephan Wulf - ODDO BHF Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Half Year Report 2024 Conference Call. I am Udith, the Chorus Call Operator.

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
accesswire.com13 August 2024 Sentiment: POSITIVE

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec HAMBURG, GERMANY / ACCESSWIRE / August 13, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced further strong progress of the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and programme-based achievements trigger payments of in total US$ 75 m to Evotec.

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
accesswire.com08 August 2024 Sentiment: POSITIVE

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / August 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further research.

  • 1(current)

What type of business is Evotec SE?

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

What sector is Evotec SE in?

Evotec SE is in the Healthcare sector

What industry is Evotec SE in?

Evotec SE is in the Drug Manufacturers - Specialty & Generic industry

What country is Evotec SE from?

Evotec SE is headquartered in Germany

When did Evotec SE go public?

Evotec SE initial public offering (IPO) was on 05 February 2004

What is Evotec SE website?

https://www.evotec.com

Is Evotec SE in the S&P 500?

No, Evotec SE is not included in the S&P 500 index

Is Evotec SE in the NASDAQ 100?

No, Evotec SE is not included in the NASDAQ 100 index

Is Evotec SE in the Dow Jones?

No, Evotec SE is not included in the Dow Jones index

When was Evotec SE the previous earnings report?

No data

When does Evotec SE earnings report?

The next expected earnings date for Evotec SE is 08 November 2024